X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Wockhardt - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs WOCKHARDT LTD. - Comparison Results

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES WOCKHARDT LTD. VENUS REMEDIES/
WOCKHARDT LTD.
 
P/E (TTM) x -885.7 18.3 - View Chart
P/BV x 0.3 1.9 13.9% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 VENUS REMEDIES   WOCKHARDT LTD.
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
WOCKHARDT LTD.
Mar-16
VENUS REMEDIES/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs2182,000 10.9%   
Low Rs82706 11.6%   
Sales per share (Unadj.) Rs365.6403.7 90.6%  
Earnings per share (Unadj.) Rs1.529.5 5.0%  
Cash flow per share (Unadj.) Rs37.942.4 89.5%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs382.5323.4 118.3%  
Shares outstanding (eoy) m11.44110.51 10.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.43.4 12.2%   
Avg P/E ratio x101.045.9 219.9%  
P/CF ratio (eoy) x4.031.9 12.4%  
Price / Book Value ratio x0.44.2 9.4%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,717149,509 1.1%   
No. of employees `0001.07.4 13.8%   
Total wages/salary Rs m3249,443 3.4%   
Avg. sales/employee Rs Th4,100.76,048.6 67.8%   
Avg. wages/employee Rs Th318.01,280.2 24.8%   
Avg. net profit/employee Rs Th16.7441.5 3.8%   
INCOME DATA
Net Sales Rs m4,18344,614 9.4%  
Other income Rs m20970 2.1%   
Total revenues Rs m4,20345,584 9.2%   
Gross profit Rs m8125,038 16.1%  
Depreciation Rs m4171,426 29.2%   
Interest Rs m3801,012 37.5%   
Profit before tax Rs m353,570 1.0%   
Minority Interest Rs m0-65 0.0%   
Prior Period Items Rs m06 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m18255 7.1%   
Profit after tax Rs m173,257 0.5%  
Gross profit margin %19.411.3 171.8%  
Effective tax rate %51.67.1 722.5%   
Net profit margin %0.47.3 5.6%  
BALANCE SHEET DATA
Current assets Rs m2,77139,906 6.9%   
Current liabilities Rs m1,93118,423 10.5%   
Net working cap to sales %20.148.2 41.7%  
Current ratio x1.42.2 66.2%  
Inventory Days Days12590 138.7%  
Debtors Days Days5498 54.7%  
Net fixed assets Rs m5,32835,832 14.9%   
Share capital Rs m114553 20.7%   
"Free" reserves Rs m4,17730,370 13.8%   
Net worth Rs m4,37635,739 12.2%   
Long term debt Rs m1,91116,542 11.5%   
Total assets Rs m8,42879,522 10.6%  
Interest coverage x1.14.5 24.1%   
Debt to equity ratio x0.40.5 94.3%  
Sales to assets ratio x0.50.6 88.5%   
Return on assets %4.75.4 87.7%  
Return on equity %0.49.1 4.3%  
Return on capital %6.68.7 76.3%  
Exports to sales %011.6 0.0%   
Imports to sales %20.54.5 460.0%   
Exports (fob) Rs mNA5,177 0.0%   
Imports (cif) Rs m8581,990 43.1%   
Fx inflow Rs m07,589 0.0%   
Fx outflow Rs m8582,878 29.8%   
Net fx Rs m-8584,711 -18.2%   
CASH FLOW
From Operations Rs m469716 65.5%  
From Investments Rs m29-8,182 -0.4%  
From Financial Activity Rs m-4642,543 -18.2%  
Net Cashflow Rs m35-4,923 -0.7%  

Share Holding

Indian Promoters % 32.9 74.5 44.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 2.3 7.8%  
FIIs % 0.6 7.7 7.5%  
ADR/GDR % 0.0 0.1 -  
Free float % 66.4 15.4 431.2%  
Shareholders   20,121 67,757 29.7%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  CADILA HEALTHCARE  GSK PHARMA  PANACEA BIOTECH  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Marginally Higher; Pharma Sector Up 2.4%(11:30 am)

Stock markets in India are presently trading near the dotted line with positive bias. Sectoral indices are trading on a mixed note with stocks in the healthcare sector.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

Aug 21, 2017

Most Indians who cannot find jobs, look at becoming self-employed.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

Aug 22, 2017

Post demonetisation, a cut in bank savings deposits rates was in the offing.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Aug 24, 2017 12:13 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS